Colorectal Adenocarcinoma

P=N/A, N=430, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting

Tragically, the patient experienced respiratory decompensation and passed away 10 weeks after the treatment. This case underscores the potential of FAP-targeted radioligand therapy in managing advanced colon cancer and suggests that earlier intervention might be beneficial.

These findings reveal the dual oncogenic function of NSUN2 in COAD-it not only propels tumor progression through direct signaling activation but also enables immune evasion by attenuating anti-tumor immunity. In summary, this study systematically clarifies how NSUN2 promotes COAD development by simultaneously activating the Wnt/β-catenin pathway and suppressing CD8+ T-cell-mediated immunity, providing a strong mechanistic foundation for its potential as a therapeutic target in future COAD treatment strategies.

KIF15 may serve as a potential biomarker and oncogenic factor in multiple cancer types.

Age, sex, race, tumor location, histology and grade, lymph node involvement, and carcinoembryonic antigen levels were independently associated with perineural invasion. Perineural invasion was an independent predictor of liver and lung metastases and worse overall survival and cancer-specific survival. The Cleveland Clinic Florida-Perineural Invasion Prediction score had an excellent negative predictive value in excluding patients without perineural invasion. Pending those trials, these findings may be considered in multidisciplinary team management conferences and in shared decision-making.

Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial...This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.

Systemic administration of anti-SIRPα-cGAMP conjugate significantly inhibited tumor growth in a mouse model of colon adenocarcinoma and improved survival in vivo by simultaneously blocking the CD47-SIRPα "do not eat me" checkpoint and selectively delivering the STING agonist to myeloid cells. These findings suggest that targeted immunostimulatory ADCs may be an effective strategy for overcoming immune resistance in solid tumors.

P2, N=48, Active, not recruiting, University of Colorado, Denver | Trial completion date: Feb 2026 --> Feb 2027

P=N/A, N=70, Not yet recruiting, University Hospital, Angers | Trial completion date: Oct 2027 --> Jun 2028 | Initiation date: Sep 2025 --> May 2026 | Trial primary completion date: Sep 2027 --> May 2028

P=N/A, N=71, Terminated, Istituto Oncologico Veneto IRCCS | Active, not recruiting --> Terminated; problems encountered during the patient recruitment phase which led to the pre-established recruitment objectives not being met.

Rectal cancer recurrence remains a major therapeutic challenge, particularly in patients unresponsive to conventional regimens. While previous studies have demonstrated limited benefit of immunotherapy in this tumor subtype, the present findings suggest an emerging therapeutic opportunity that warrants prospective evaluation to confirm efficacy, explore the mechanistic basis, and identify biomarkers predictive of durable response beyond the absence of liver metastases. More effective combinatorial regimens like zanzalintinib and atezolizumb (STELLAR-303) trial, as well as newer generation of CTLA-4 inhibitors like botensilimab, vilastobart, and muzastotug are showing more promise for patients with MSS colorectal cancers in particular who do not have liver metastases (NLM).

Accurate assessment of lymphatic metastasis risk in rectal cancer is crucial for clinical decision-making and personalized treatment optimization. Diffusion kurtosis imaging-derived parameters and habitat radiomic features can quantify and characterize intratumoral heterogeneity. The combined model provides higher predictive performance for LVI and LNM in rectal cancer.